01-09-2019 | Metastasis | Original Article
Successful combination therapy of systemic checkpoint inhibitors and intralesional interleukin-2 in patients with metastatic melanoma with primary therapeutic resistance to checkpoint inhibitors alone
Published in: Cancer Immunology, Immunotherapy | Issue 9/2019
Login to get access